Skip to content
type1.science

Omnipod GO (pump)

Insulet

An FDA-cleared basal-only tubeless pod for adults with type 2 diabetes that delivered one fixed daily rate without a controller, app, phone, or CGM. Insulet ran a commercial pilot but decided in 2024 not to commercialize it, choosing Omnipod 5 for type 2 diabetes instead. It was never a T1D product.

DiscontinuedRegulator-approvedpumptubelesspatchbasal-onlyt2d-onlydiscontinued

The scorecard

Interoperability4

Deliberately standalone: it connects to no CGM, no AID algorithm, no DIY loop and no phone — a closed, single-purpose basal device by design.

Reliability68

Built on Insulet's mature, waterproof Pod platform with automated cannula insertion and an occlusion hazard alarm (~3-5 U missed); fixed-rate delivery is simple, but it shares single-use Pods' occasional early-failure risk and has a far smaller track record than Omnipod 5.

Form factor92

Fully tubeless, waterproof patch (IP28, ~7.6 m/60 min) worn directly on the body — the category's convenience benchmark, with no tubing and no handheld to carry.

Phone control2

No phone, app or controller of any kind — and no bolus capability; the daily dose is fixed at the factory and cannot be adjusted by the user.

Capacity50

Holds up to 200 U of U-100 insulin (min 85 U fill) over ~72 h wear, but the usable fixed daily dose is capped at 10-40 U/day across seven preset Pods, and the whole Pod is discarded each change.

Access & cost0

No commercial access. Insulet says it learned from a limited pilot and decided in 2024 not to move forward with commercialization, writing off related inventory and focusing its type 2 strategy on Omnipod 5.[1]

The full picture

The Omnipod GO is the simplest member of the Omnipod hardware family: a tubeless patch pod that delivers one fixed daily dose of rapid-acting insulin and nothing else. It was FDA-cleared in April 2023 for adults (18+) with type 2 diabetes who would otherwise take daily long-acting (basal) injections — it is not indicated for type 1 diabetes, so its direct T1D relevance is limited; it is documented here for completeness of the Omnipod family.12

Form factor: a tubeless patch, no tubing. Like its Omnipod siblings it is a small, self-contained, waterproof pod worn directly on the skin, with no tubing and no separate insulin line.13 It is built on the same Pod platform as Omnipod DASH/5, which is waterproof to IP28 (up to ~7.6 m / 25 ft for 60 minutes) and inserts its cannula automatically.45

Reservoir, cannula and wear. Each Pod is filled with U-100 rapid-acting insulin (the shared Pod holds up to 200 units, with a minimum fill of about 85 units) and worn for up to 72 hours (3 days) before being replaced as a whole single-use unit.52 A small flexible cannula is inserted automatically when the Pod is activated by snapping off a hard plastic tab — after filling, the Pod prepares to insert roughly 3 minutes after an amber light appears, so it must be on the skin before then.6

The defining limitation: a fixed daily rate, no bolus. The Omnipod GO delivers a fixed, continuous basal rate only. It comes in seven pre-programmed daily rates from 10 to 40 units per day; the rate is set at manufacture and cannot be adjusted by the user.12 To change the dose, a clinician prescribes a different preset Pod — there is no on-device programming, and there is no mealtime bolus function at all.6

No controller, no phone, no CGM, no AID, no DIY. Uniquely among insulin pumps, the Omnipod GO operates without any handheld controller, app or smartphone.12 It does not connect to a continuous glucose monitor, does not run or pair with any automated-insulin-delivery (AID) algorithm, and does not work with DIY/open-source loops — it is a standalone, single-function basal device.13 Getting started requires a healthcare provider to train the user with an Omnipod GO Sample Kit.6

Occlusion detection and reliability. It shares the Insulet Pod's safety mechanics, including automated cannula insertion and a hazard alarm that sounds when an occlusion (a blockage averaging roughly 3-5 units of missed insulin) is detected.65 The underlying Pod hardware has a long real-world track record across the Omnipod line, though the GO itself is far newer and narrower in use.4

Compatible insulins. It is cleared for U-100 NovoLog, Fiasp, Humalog, Admelog and Lyumjev.12

What happened to access. Omnipod GO did reach a limited US commercial pilot, but the planned broad launch did not happen. In its 2025 Form 10-K, filed in February 2026, Insulet says it decided in 2024 not to move forward with commercialization after learning from the pilot and the positive Omnipod 5 type 2 trial. The company recorded a $13.5 million charge for inventory components it would no longer use.7 This record is therefore discontinued—not "available" and not "coming soon."

Insulet's live type 2 strategy now runs through the full-featured Omnipod 5 and later automated systems, not through this fixed-rate basal pod.7 For type 1 diabetes, GO was always out of scope by indication; its value here is historical completeness and a warning that an FDA clearance plus a pilot is not the same thing as a product launch.

References

  1. Insulet Corporation. Insulet Announces FDA Clearance of Omnipod GO, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes. Insulet investor news (Apr 25, 2023; T2D adults 18+, fixed rate, seven preset daily rates 10-40 U/day, 72 h wear, tubeless/waterproof, no handheld controller, U-100 insulins). https://investors.insulet.com/news/news-details/2023/Insulet-Announces-FDA-Clearance-of-Omnipod-GO-a-First-of-its-Kind-Basal-Only-Insulin-Pod-Further-Simplifying-Life-for-People-with-Type-2-Diabetes/default.aspx ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  2. Insulet Corporation. FDA Clearance of Omnipod GO — basal-only insulin pod (BusinessWire press release, Apr 25, 2023; designed for the >3 million people using basal insulin or transitioning to insulin therapy for type 2 diabetes; planned US commercialization 2024). https://www.businesswire.com/news/home/20230424006026/en/Insulet-Announces-FDA-Clearance-of-Omnipod-GO-a-First-of-its-Kind-Basal-Only-Insulin-Pod-Further-Simplifying-Life-for-People-with-Type-2-Diabetes ↩ ↩2 ↩3 ↩4 ↩5

  3. Drug Delivery Business News. FDA clears basal-only insulin pod for type 2 diabetes from Insulet (Apr 2023; standalone tubeless waterproof pod, fixed rate, no handheld device, US pilot/2024 commercialization). https://www.drugdeliverybusiness.com/fda-clears-basal-insulin-pod-insulet-diabetes/ ↩ ↩2

  4. Ly TT, Layne JE, Huyett LM, Nazzaro D, O'Connor JB. Novel Bluetooth-Enabled Tubeless Insulin Pump: Innovating Pump Therapy for Patients in the Digital Age. J Diabetes Sci Technol (2018); 13(1):20-26. According to PubMed (shared Insulet Pod platform: tubeless waterproof IP28 housing, up to 200 U U-100, automated cannula insertion). https://pmc.ncbi.nlm.nih.gov/articles/PMC6313290/ (DOI) ↩ ↩2

  5. Insulet (Omnipod). Omnipod GO Insulin Delivery Device — Quick Start Guide (US English) (Pod fill 85-200 U U-100, ~72 h wear, automated cannula, IP28 waterproofing, occlusion hazard alarm). https://www.omnipod.com/sites/default/files/GO_Quick_Start_Guide_US_English.pdf ↩ ↩2 ↩3

  6. Insulet (Omnipod). Omnipod GO Frequently Asked Questions (fixed preset daily rate not user-adjustable; HCP changes prescription to change dose; activation by snapping off the tab with ~3-minute insertion window; HCP training via Omnipod GO Sample Kit; occlusion alarm at ~3-5 U missed). https://www.omnipod.com/current-podders/resources/omnipod-go/faqs ↩ ↩2 ↩3 ↩4

  7. Insulet Corporation. Annual Report on Form 10-K for the year ended 31 December 2025 (filed February 2026; decision in 2024 not to commercialize Omnipod GO; $13.5 million inventory charge). https://www.sec.gov/Archives/edgar/data/1145197/000114519726000028/podd-20251231.htm ↩ ↩2

Sources

  1. [1]Insulet 2025 Form 10-K — decision not to commercialize Omnipod GO · manufacturer · 2026-02-19 — Insulet states it decided in 2024 not to move forward with Omnipod GO commercialization after its pilot and recorded a $13.5 million inventory charge, while prioritizing Omnipod 5 for type 2 diabetes.